Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (27223)	1/6/1999 9:36:00 AM
From: Henry Niman	Respond to of 32384

Yesterday's WSJ had an interesting article on Biotech investing during the past decade. See Biotech Boom table at biocognizance.com

To: Machaon who wrote (27223)	1/6/1999 10:16:00 AM
From: Mudcat	Read Replies (1) \| Respond to of 32384

<Actually, both of us were wrong> No Bob, only you were wrong. The cash taken in by Lgnd from the Elan and warrant redemption deals would affect the Balance Sheet and Cash Flow Statement. It would have little if any effect on the Income Statement. These are the three main financial statements for a company. I agree that investors may look at cash on hand when investing in biotechs but this info is not on the income statement and DOES NOT impact earnings. Maybe you need to take a basic Finance & Accounting Course before you try to inflict your knowledge or lack of it on this thread.